HK1199444A1 - -二氨基- -吩噻嗪化合物的製備方法 - Google Patents

-二氨基- -吩噻嗪化合物的製備方法

Info

Publication number
HK1199444A1
HK1199444A1 HK14112923.1A HK14112923A HK1199444A1 HK 1199444 A1 HK1199444 A1 HK 1199444A1 HK 14112923 A HK14112923 A HK 14112923A HK 1199444 A1 HK1199444 A1 HK 1199444A1
Authority
HK
Hong Kong
Prior art keywords
4alkyl
4alkenyl
halogenated
independently selected
diamino
Prior art date
Application number
HK14112923.1A
Other languages
English (en)
Inventor
克勞德‧
‧維希克
珍妮特‧
‧里卡德
查爾斯‧
‧哈林頓
戴維‧霍斯利
約翰‧
‧斯托雷
科林‧馬歇爾
詹姆斯‧
‧辛克萊
托馬斯‧
‧巴德利
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38421429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of HK1199444A1 publication Critical patent/HK1199444A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK14112923.1A 2006-03-29 2014-12-24 -二氨基- -吩噻嗪化合物的製備方法 HK1199444A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78669006P 2006-03-29 2006-03-29

Publications (1)

Publication Number Publication Date
HK1199444A1 true HK1199444A1 (zh) 2015-07-03

Family

ID=38421429

Family Applications (4)

Application Number Title Priority Date Filing Date
HK09105064.1A HK1126480A1 (en) 2006-03-29 2009-06-05 3, 7-diamino-10h-phenothiazine salts and their use
HK14112923.1A HK1199444A1 (zh) 2006-03-29 2014-12-24 -二氨基- -吩噻嗪化合物的製備方法
HK15109987.9A HK1209417A1 (zh) 2006-03-29 2015-10-13 -二氨基- -吩噻嗪化合物鹽及其用途
HK15110959.1A HK1210047A1 (zh) 2006-03-29 2015-11-06 -二氨基- -吩噻嗪化合物鹽及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09105064.1A HK1126480A1 (en) 2006-03-29 2009-06-05 3, 7-diamino-10h-phenothiazine salts and their use

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15109987.9A HK1209417A1 (zh) 2006-03-29 2015-10-13 -二氨基- -吩噻嗪化合物鹽及其用途
HK15110959.1A HK1210047A1 (zh) 2006-03-29 2015-11-06 -二氨基- -吩噻嗪化合物鹽及其用途

Country Status (19)

Country Link
US (3) US7888350B2 (zh)
EP (1) EP2013191B3 (zh)
JP (3) JP5520043B2 (zh)
KR (1) KR100983301B1 (zh)
CN (5) CN104119294B (zh)
AT (1) ATE478058T3 (zh)
AU (1) AU2007231124B2 (zh)
CA (1) CA2646163C (zh)
DE (1) DE602007008550D1 (zh)
DK (1) DK2013191T6 (zh)
EA (1) EA014552B1 (zh)
ES (1) ES2349322T7 (zh)
HK (4) HK1126480A1 (zh)
HR (1) HRP20100614T4 (zh)
IL (2) IL194516A (zh)
MY (1) MY143757A (zh)
PL (1) PL2013191T6 (zh)
PT (1) PT2013191E (zh)
WO (1) WO2007110627A2 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN103735554B (zh) 2006-03-29 2018-03-20 维斯塔实验室有限公司 蛋白聚集抑制剂
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
CN101631780A (zh) * 2007-04-03 2010-01-20 普罗瑟塔生物谐成公司 用于抗病毒治疗的吩噻嗪衍生物
SI2167095T1 (sl) * 2007-06-19 2019-09-30 Wista Laboratories Ltd. Fenotiazinske spojine za zdravljenje blage kognitivne motnje
FR2920775B1 (fr) * 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations.
EP2954932B1 (en) * 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Therapeutic use of diaminophenothiazines
CN102307878B (zh) 2008-12-10 2014-10-15 维斯塔实验室有限公司 3，6-二取代的呫吨鎓盐
PT2480541E (pt) * 2009-09-24 2016-01-26 Wista Lab Ltd Hidratos de cloreto de metiltiónio cristalino (azul de metileno)
EP2480540B1 (en) * 2009-09-24 2017-11-29 WisTa Laboratories Ltd. Methylthioninium chloride pentahydrate, preparation and pharmaceutical use thereof
WO2011137447A1 (en) 2010-04-30 2011-11-03 Prostetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
CA2818068C (en) 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
SI2673266T1 (sl) 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) * 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
MY201804A (en) * 2016-07-25 2024-03-19 Wista Laboratories Ltd Administration and dosage of diaminophenothiazines
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) * 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN107253936B (zh) * 2017-06-23 2021-07-23 复旦大学 一类可用于次氯酸检测的荧光探针及其制备方法和应用
CN108129418A (zh) * 2017-12-22 2018-06-08 郑州大学 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用
AU2019308873A1 (en) 2018-07-26 2021-02-04 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
JP7401531B2 (ja) 2018-09-05 2023-12-19 ゲンティング タークス ダイアグノースティク センター エスディエヌ ビーエイチディ 神経変性疾患のためのネットワーク法
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
MX2022013883A (es) 2020-05-05 2022-11-30 Wista Lab Ltd Compuestos de metiltioninio para uso en el tratamiento de covid-19.
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
CN115916211A (zh) 2020-05-05 2023-04-04 维斯塔实验室有限公司 用于治疗低氧血症的甲基硫堇鎓化合物
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
DE102020212508A1 (de) 2020-10-02 2022-04-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (zh) 1957-07-17
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
JPS52105931A (en) * 1976-03-02 1977-09-06 Mita Industrial Co Ltd New leuco coloring matters and process for manufacture thereof
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
US5220009A (en) * 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
CA2125298A1 (en) 1991-12-06 1993-06-10 Eva-Maria Mandelkow Tools for the diagnosis and treatment of alzheimer's disease
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
CA2196529A1 (en) 1994-08-08 1996-02-22 Peter Davies Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
JP2001514617A (ja) 1997-01-21 2001-09-11 ジ・アメリカン・ナショナル・レッド・クロス 両親媒性フェノチアジン−５−イウム染料と光による全血および血液成分の細胞内および細胞外汚染除去
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
EP1248518A2 (en) 2000-01-21 2002-10-16 PHARMACIA & UPJOHN COMPANY Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
AU2004295148A1 (en) 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2007056439A1 (en) 2005-11-08 2007-05-18 Collegium Pharmaceutical, Inc. Salts of methylene blue and its derivatives
CN104119294B (zh) * 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN103735554B (zh) 2006-03-29 2018-03-20 维斯塔实验室有限公司 蛋白聚集抑制剂
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
SI2167095T1 (sl) 2007-06-19 2019-09-30 Wista Laboratories Ltd. Fenotiazinske spojine za zdravljenje blage kognitivne motnje
EP2954932B1 (en) 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Therapeutic use of diaminophenothiazines
SI2673266T1 (sl) 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba

Also Published As

Publication number Publication date
KR100983301B1 (ko) 2010-09-20
US20090054419A1 (en) 2009-02-26
CN104529939A (zh) 2015-04-22
KR20080110879A (ko) 2008-12-19
WO2007110627A3 (en) 2007-11-22
CN101460472A (zh) 2009-06-17
EP2013191B3 (en) 2019-02-27
HRP20100614T4 (hr) 2019-08-09
DK2013191T6 (en) 2019-04-23
EP2013191A2 (en) 2009-01-14
CN104529939B (zh) 2019-05-07
IL194516A0 (en) 2009-08-03
JP2009531403A (ja) 2009-09-03
ATE478058T3 (de) 2010-09-15
HRP20100614T1 (en) 2010-12-31
AU2007231124A1 (en) 2007-10-04
CN109384741A (zh) 2019-02-26
JP5814957B2 (ja) 2015-11-17
ES2349322T7 (es) 2019-10-17
US20220152038A1 (en) 2022-05-19
IL231890A (en) 2016-10-31
CN104119294B (zh) 2018-10-30
IL231890A0 (en) 2014-05-28
EP2013191B1 (en) 2010-08-18
JP2014055165A (ja) 2014-03-27
CA2646163C (en) 2011-03-15
US20160051559A1 (en) 2016-02-25
JP2013121985A (ja) 2013-06-20
MY143757A (en) 2011-07-15
AU2007231124B2 (en) 2013-02-21
US11344558B2 (en) 2022-05-31
JP5520043B2 (ja) 2014-06-11
CN104606199A (zh) 2015-05-13
PT2013191E (pt) 2010-10-29
CA2646163F (en) 2007-10-04
US7888350B2 (en) 2011-02-15
EA014552B1 (ru) 2010-12-30
DK2013191T3 (da) 2010-11-22
PL2013191T3 (pl) 2011-02-28
US11951110B2 (en) 2024-04-09
HK1209417A1 (zh) 2016-04-01
PL2013191T6 (pl) 2019-07-31
CN104119294A (zh) 2014-10-29
CN109384741B (zh) 2023-01-06
CN101460472B (zh) 2015-06-17
HK1210047A1 (zh) 2016-04-15
CA2646163A1 (en) 2007-10-04
WO2007110627A2 (en) 2007-10-04
HK1126480A1 (en) 2009-09-04
EA200870384A1 (ru) 2009-04-28
CN104606199B (zh) 2022-09-13
ES2349322T3 (es) 2010-12-29
IL194516A (en) 2015-02-26
DE602007008550D1 (de) 2010-09-30

Similar Documents

Publication Publication Date Title
HK1199444A1 (zh) -二氨基- -吩噻嗪化合物的製備方法
MY139446A (en) Novel quinoline derivatives
PL2018379T3 (pl) Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium
TW200728307A (en) Novel spirochromanone derivatives
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
UA100132C2 (en) Isoxazolo-pyridine derivatives
UA91129C2 (ru) Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
TW200640900A (en) 1-(2h)-isoquinolone derivative
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
TW200626553A (en) Novel compounds
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
WO2007143523A3 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
TW200704633A (en) Process for the preparation of sulfonamide derivatives
WO2007075838A3 (en) Pure and stable tiotropium bromide
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
TW200502222A (en) Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
WO2005033279A3 (en) Discovery of novel soluble crystalline anesthetics
WO2009148291A3 (en) 3- or 4-substituted piperidine compounds
TWI367097B (zh)